News for Prelude Therapeutics Incorporated (PRLD)

Shares of Braze, Inc. BRZE rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issue...

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with

Shares of Lattice Semiconductor Corporation LSCC rose sharply in pre-market trading after the company reported its fourth-quarter financial results after Monday...

Prelude Therapeutics' interim CFO Bryant Lim buys $22,637 in stock

PRLD Stock Touches 52-Week Low at $0.93 Amid Market Challenges

WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) ( PRLD), a clinical-stage precision oncology company, announce

PRLD stock touches 52-week low at $1.65 amid market challenges

-  Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and...

Prelude reports safety of new cancer drug at ESMO Congress

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13,...

U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Wednesday. Shares of UBS Group AG UBS rose during Wednesday's session following st...

Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for...

WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company,...

First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data...

The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...

U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X ...

This morning 533 companies reached new 52-week highs. Intriguing Points: The largest company on a market cap basis to set a new 52-week high ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 ...